Related Experiment Videos
Prevention of adriamycin (ADR)-induced cardiotoxicity in rats using methylprednisolone (MP)
Abstract:
Adriamycin (ADR) is a useful antitumor agent but causes severe cardiotoxicity requiring dose limitation. Methylprednisolone (MP) has been shown to stabilize cell membranes and, in ischemic heart models, to protect mitochondria lysosomes and sarcolemma. The purpose of this study was to determine if MP could prevent ADR-induced cardiotoxicity in rats. Twenty-eight normal, male, Wistar rats were placed in two groups of 14 each. One group received ADR 2 mg/kg iv weekly for 3 weeks, followed by 2 mg/kg subcutaneously weekly. The other group received the same dosage of ADR but also MP 20 mg/kg subcutaneously 3 hr before, with ADR and 3 hr after ADR. Seven rats in each group were sacrificed after the 10th week of treatment. At autopsy 7/7 (100%) of the rats in the ADR groups had obvious ascites and pleural effusion whereas 0/7 in the ADR + MP group developed this complication (P less than 0.01). Microscopic examination of the hearts revealed vacuole formation, loss of muscle mass, tapering off of myocardial cells, or inflammatory changes in 7/7 (100%) of the rats in the ADR group and in 2/7 (28%) of the ADR and MP group (P less than 0.05). Among the rats left to monitor survival, at 11 weeks from the initiation of treatment, 4/7 (57%) in the ADR group and 7/7 (100%) in the ADR + MP group were alive. These data indicate that MP provides some protection from Adriamycin-induced cardiotoxicity in rats.
Insights
Methylprednisolone (MP) protects against Adriamycin (ADR)-induced cardiotoxicity in rats. MP treatment significantly reduced fluid buildup and heart damage, improving survival rates in rats receiving ADR antitumor therapy.
Area of Science:
- Cardiology
- Pharmacology
- Oncology
Background:
- Adriamycin (ADR) is an effective antitumor drug but its use is limited by severe cardiotoxicity.
- Methylprednisolone (MP) is known to stabilize cell membranes and protect cardiac structures in ischemic models.
Purpose of the Study:
- To investigate the protective effects of Methylprednisolone (MP) against Adriamycin (ADR)-induced cardiotoxicity in a rat model.
Main Methods:
- Wistar rats were divided into two groups: one receiving ADR alone, and another receiving ADR with MP.
- MP was administered subcutaneously before, during, and after ADR injections over a 3-week period.
- Cardiac function and survival were assessed after 10 and 11 weeks, respectively.
Main Results:
- Rats treated with ADR alone showed 100% incidence of ascites and pleural effusion, compared to 0% in the ADR + MP group (P<0.01).
- Microscopic analysis revealed significant cardiac damage in 100% of ADR-treated rats versus 28% in the ADR + MP group (P<0.05).
- Survival rates at 11 weeks were 57% for ADR and 100% for ADR + MP treated rats.
Conclusions:
- Methylprednisolone (MP) demonstrates significant protective effects against Adriamycin (ADR)-induced cardiotoxicity in rats.
- MP may be a viable co-therapy to mitigate the cardiac side effects of Adriamycin chemotherapy.